iwCLL

1-888-476-9129 info@bioascend.com

Menu

 

Symposia

The XVII International Workshop on Chronic Lymphocytic Leukemia (iwCLL) in New York, New York, offers the opportunity for industry-supported satellite symposia (ISS) to be held in conjunction with its biennial meeting. The symposia play an important role in supporting the needs of iwCLL participants by offering additional educational opportunities. Listed below are the dates, times, agendas, and additional program information for the confirmed ISS symposia being held during iwCLL 2017.

 

Sunday, May 14, 2017

Marriott Marquis – 6th Floor, Broadway Ballroom

1:30-2:00 pm Registration

2:00-4:00 pm Scientific Program

 

Exploring the CLL Treatment Tool Kit: A Master Class on Modern Therapy, Clinical Trials, and Precision Medicine

 

Chair and Faculty:

William G. Wierda, MD, PhD – Panel Chair and Presenter

Asher A. Chanan-Khan, MD – Co-Presenter

Matthew S. Davids, MD, MMSc – Co-Presenter

 

Program Overview:

The recent emergence of multiple, novel agent classes in chronic lymphocytic leukemia (CLL) has expanded the hematology-oncology professional’s “tool kit” for patient care. Expanded options for treatment mean more choices for clinicians and more opportunities to fine-tune therapy to the needs of a given patient. PeerView’s latest live event will offer professionals a “Master Class” on the meaning of precision medicine in CLL in the modern era, including insights on how to select and sequence novel agent classes (BTK inhibitors, Bcl2 -targeting agents, and next-generation anti-CD20 antibodies), while addressing key practical considerations such as prognostic assessment and adverse event management. In addition, our panel of experts will offer case-based illustrations of a more tailored approach to therapy in CLL and review important ongoing clinical trials that may further crystallize the use of newer therapeutics in the CLL setting.

This CME/CE/CPE activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education; this activity is also coprovided by Medical Learning Institute, Inc.
This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC.

To register for the symposia, please click HERE or call 1-877-833-6141.

 

Agenda:
1:30 pm: Registration

2:00 pm: Opening the CLL Tool Kit: An Introduction to the Impact of Novel Therapy
William G. Wierda, MD, PhD

Master Classes on CLL

2:10 pm: Starting With Precision Medicine for the Newly Diagnosed Patient
William G. Wierda, MD, PhD

2:30 pm: Upfront Management of CLL and the New Treatment Tool Kit
Matthew S. Davids, MD, MMSc

3:05 pm: Sequencing Therapy for the CLL Patient Across the Disease Continuum
Asher A. Chanan-Khan, MD

3:40 – 4:00 pm
Symposium Summary and Audience Q&A (Panel)

 

Monday, May 15, 2017

Marriott Marquis – 6th Floor, Broadway Ballroom
10:45 am -12:45 pm Scientific Program

Evolution of Treatment in Relapsed/Refractory CLL: Past, Present, and Future

Industry-Supported Symposium supported by AbbVie Inc.

 

Program Objectives:

·      Review data from currently approved agents for treatment of R/R CLL

·      Discuss potential shift in treatment paradigm in future and trial designs of emerging agents/regimens

·      Sequencing currently approved agents in R/R CLL

 

Chair and Faculty:

Susan O’Brien, MD – Chair

John Gribben, DSc, FRCP, FRC Path, FMed Sci – Faculty

Michael Hallek, MD – Faculty

John Seymour, MD, MPH

 

Agenda:

10:45 am – 10:55 pm: Chair Welcome
Susan O’Brien

10:55 am – 11:10 pm: The Goals of Treatment for Patients With Relapsed/Refractory (R/R) CLL
John Seymour

11:10 am – 11:35 pm: Current  Treatment Options for R/R CLL in the US
Susan O’Brien

11:35 am – 12:00 pm: Focus on del(17p): Outcomes, Sequencing of Therapy, and Other Considerations
John Gribben

12:00 pm – 12:15 pm: Future Perspectives: The Role of MRD in Clinical Decision-Making
John Seymour

12:15 pm – 12:40 pm: Potential Innovative Approaches on the Horizon for Patients with R/R CLL
Michael Hallek

12:40 – 12:45 pm: Closing Remarks
Susan O’Brien